Scholar Rock (SRRK) Competitors

Scholar Rock (NASDAQ:SRRK) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, community ranking, dividends, earnings and risk.

Do analysts rate SRRK or HUMA?

Scholar Rock currently has a consensus target price of $25.60, indicating a potential upside of 303.15%. Humacyte has a consensus target price of $8.19, indicating a potential upside of 121.28%. Given Scholar Rock's higher possible upside, equities analysts plainly believe Scholar Rock is more favorable than Humacyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Humacyte	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger earnings & valuation, SRRK or HUMA?

Humacyte has lower revenue, but higher earnings than Scholar Rock. Humacyte is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	$33.19 million	10.39	-$134.50 million	-$2.56	-2.48
Humacyte	$1.57 million	243.52	-$11.97 million	-$0.30	-12.33

Is SRRK or HUMA more profitable?

Humacyte has a net margin of 1,971.30% compared to Scholar Rock's net margin of 0.00%. Scholar Rock's return on equity of -59.71% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-59.71%	-44.63%
Humacyte	1,971.30%	-76.90%	-41.12%

Which has more volatility and risk, SRRK or HUMA?

Scholar Rock has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Does the media prefer SRRK or HUMA?

In the previous week, Humacyte had 6 more articles in the media than Scholar Rock. MarketBeat recorded 8 mentions for Humacyte and 2 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.07 beat Humacyte's score of -0.06 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of SRRK or HUMA?

91.6% of Scholar Rock shares are held by institutional investors. Comparatively, 13.1% of Humacyte shares are held by institutional investors. 2.1% of Scholar Rock shares are held by insiders. Comparatively, 25.0% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community believe in SRRK or HUMA?

Scholar Rock received 128 more outperform votes than Humacyte when rated by MarketBeat users. Likewise, 61.19% of users gave Scholar Rock an outperform vote while only 31.58% of users gave Humacyte an outperform vote.

Company	Underperform	Outperform
Scholar Rock	Outperform Votes 134 61.19%	Underperform Votes 85 38.81%
Humacyte	Outperform Votes 6 31.58%	Underperform Votes 13 68.42%

Summary

Scholar Rock beats Humacyte on 9 of the 17 factors compared between the two stocks.